Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC To Issue IPO To Capitalize On First Quarter Turnaround, Health Awareness

This article was originally published in The Tan Sheet

Executive Summary

GNC hopes to raise $345 mil. through an initial public offering of shares, according to a preliminary prospectus filed May 28 with the Securities & Exchange Commission

You may also be interested in...



Making The Most Of Recent Earnings, GNC Files IPO

Citing a strong first quarter, GNC is making good on its decision to file an IPO when the market turned favorable. "Our recent results have been very strong," Ben Pratt, director of corporate communications, told "The Tan Sheet". "We always said that we would pursue an IPO when the conditions were right.

Making The Most Of Recent Earnings, GNC Files IPO

Citing a strong first quarter, GNC is making good on its decision to file an IPO when the market turned favorable. "Our recent results have been very strong," Ben Pratt, director of corporate communications, told "The Tan Sheet". "We always said that we would pursue an IPO when the conditions were right.

Making The Most Of Recent Earnings, GNC Files IPO

Citing a strong first quarter, GNC is making good on its decision to file an IPO when the market turned favorable. "Our recent results have been very strong," Ben Pratt, director of corporate communications, told "The Tan Sheet". "We always said that we would pursue an IPO when the conditions were right.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel